The purpose is to determine whether long‑term use of Admilparant is safe and does not lead to serious side effects.

Participants will take one tablet each day for several years while doctors perform regular check‑ups. At each visit routine blood work, a quick heart test called an ECG that records the heart’s electrical activity, and measurements of blood pressure and heart rate are done. The study records any side effects, changes in test results, or reasons to stop the medication, and follows each person from the start until the study ends.

The purpose of the trial is to evaluate the long‑term safety and tolerability of the study drug in this patient population. After an initial screening, participants will receive the assigned medication at regular intervals over an extended period while undergoing routine health checks, including measurements of vital signs, blood laboratory tests, and a heart test known as an electrocardiogram. Physical examinations will assess walking ability, standing up from the floor, climbing stairs, and upper‑limb function, and blood samples will be taken to monitor drug levels and any immune response. The study is open‑label, so all participants know they are receiving the investigational therapy, and it continues beyond the earlier phase of the research.

The purpose of the study is to assess the safety and tolerability of the different treatment regimens. After an initial screening visit, participants will begin a series of injection visits that continue for several months, with regular clinic appointments to check health status, record any side effects, and perform routine laboratory tests. The study follows participants for up to about four years to observe long‑term outcomes.

Safety monitoring includes tracking any new medical problems that arise during the trial. In addition, doctors will use a camera procedure called endoscopic examination to look inside the colon and evaluate improvement of the disease after about one year. This information, together with the safety data, helps determine whether the antibodies are well tolerated and potentially beneficial for people with ulcerative colitis.

Participants receive the medication by an intravenous infusion, meaning it is given through a vein, with the amount of drug increased gradually in the early part of the study to find a safe level, followed by a larger group receiving that level to see early signs of effectiveness. Throughout the study, regular blood tests are done to measure PSA (a protein that can indicate prostate cancer activity), check organ function, and look for any side effects. Imaging scans are also performed at set intervals to see if tumors shrink or stop growing. The study follows each participant for several months, recording any adverse events, changes in laboratory results, and overall health status.

The primary aim of the trial is to determine whether the new combination improves the time patients live without their disease getting worse and, for a portion of the study, also extends overall survival compared with standard care.

Participants are randomly assigned to receive either the experimental medicines or the usual therapy, with treatment given in repeated cycles of intravenous infusions and oral tablets over several months. Throughout the study, doctors monitor tumor size using imaging scans evaluated by the criteria called RECIST 1.1, record how long the disease stays stable (progression free survival), note the length of life from start of treatment (overall survival), and assess how many patients experience tumor shrinkage (objective response rate). Safety is evaluated by tracking side effects, vital signs, laboratory tests and heart rhythm recordings.

Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.

The purpose of the trial is to find out whether adding the study drug to the steroid‑taper plan can achieve better sustained remission after one year compared with the steroid taper alone. The study is designed to be randomized (participants are assigned to groups by chance) and double‑blind (neither the participants nor the doctors know which injection is being given). Over about a year, participants will attend regular visits where their symptoms, blood tests, and questionnaires about physical and mental health are checked, and any side effects will be recorded.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

The aim is to see whether the combination improves the lining of the intestine better than the injectable medication alone over a 12‑week period. Participants will receive the assigned medication(s) at regular intervals and will have routine visits where doctors may use a thin camera (a endoscopic exam) to look at the intestine and check for improvement. The study will last about three months, after which the results will be evaluated.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The main purpose of the trial is to keep participants who are still benefiting from the drug under medical supervision while safety is monitored. After joining, participants will continue to receive opnurasib on a regular schedule for as long as it remains helpful and tolerable. Visits will include simple check‑ups to record any side effects, any changes in dosage, and overall health. The study does not involve any additional invasive procedures beyond the usual care for this condition.

The purpose of the study is to compare the effects of Odevixibat with a placebo in children with Biliary Atresia. Participants will receive either Odevixibat or a placebo once daily. The study will last for up to 104 weeks, during which time the health of the participants will be closely monitored. The main focus will be on the time it takes for participants to require a liver transplant or experience other serious health issues related to their liver condition.

Throughout the study, various health parameters will be assessed, including liver function tests and overall health status. The study aims to provide valuable information on whether Odevixibat can help improve the outcomes for children with Biliary Atresia who have had the Kasai procedure. Participants will be regularly checked for any side effects or changes in their health to ensure their safety during the trial.

The purpose of the trial is to identify a safe and effective dose of the new medication, to see how well it works against these cancers, and to understand how it interacts with other treatments. Early parts of the study increase the dose to find the highest amount patients can tolerate, followed by later parts that treat specific cancer types either alone or combined with the listed drugs. A small group of participants will also receive medicines that are processed by the enzymes CYP3A4 and CYP2C8 to check for possible drug‑interaction effects.

Participants will take the study tablet each day and receive the other medicines by intravenous infusion, meaning the drugs are given through a vein. Regular clinic visits will include physical checks, blood tests, and imaging scans that are evaluated using RECIST criteria, a system that measures how tumor size changes over time. The trial will continue for several months, with close monitoring for side effects, dose adjustments if needed, and assessments of tumor response.

The main goal of the research is to find out which individuals respond best to the treatment. Participants will receive the medication for about six months, with visits at the beginning and end of the period to collect information on weight, eating behavior, and other health measures.

Key outcomes include changes in BMI (a number that compares weight to height), changes in the Binge Eating Scale (a questionnaire that measures the severity of binge eating), as well as waist‑to‑hip ratio, body composition, appetite feelings, and various blood markers. Simple explanations are provided for any technical terms, such as BMI being a standard way doctors assess whether weight is in a healthy range.

The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.

The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the study is to learn about the safety and effects of VERT-002 in treating these types of cancers. The study is divided into two parts. In the first part, researchers will determine the safest dose of VERT-002 and how well patients tolerate it. In the second part, they will further explore the drug’s effects and continue to monitor its safety. The study will help identify the best dose to use in future research.

Participants in the study will receive VERT-002 and will be closely monitored by healthcare professionals. The study will look at how the drug affects the cancer and any side effects that may occur. This research is important for developing new treatments for patients with advanced cancers that have limited options. The study is expected to continue for several years to gather comprehensive data on the drug’s effectiveness and safety.

Participants will take the study tablets once daily for about 12 weeks and will attend regular clinic visits where they will complete questionnaires and undergo simple tests. One questionnaire, the Epworth Sleepiness Scale, asks about the likelihood of falling asleep in everyday situations to measure daytime sleepiness. Another test, the Maintenance of Wakefulness Test, measures how long a person can stay awake while trying to stay alert. Throughout the study, researchers will monitor how the medication affects sleepiness and overall well‑being, while also checking for any side effects.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

Participants in the study will receive either Dupilumab, which is administered as a solution for injection in a pre-filled syringe, or a matched placebo. The purpose of the study is to see if Dupilumab can significantly reduce the itchiness of LSC over a period of 24 weeks. The study will monitor changes in the severity of itching and its impact on sleep and quality of life. Additionally, the study will track any side effects or adverse reactions to the treatment.

The trial is designed to be a randomized, double-blind, placebo-controlled study, meaning neither the participants nor the researchers will know who is receiving Dupilumab or the placebo. This approach helps ensure the results are unbiased. The study will last for approximately 24 weeks, during which participants will be regularly assessed to measure the effectiveness of the treatment and any changes in their condition.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

The purpose of the study is to understand how aspirin affects the chances of cancer coming back and the overall survival of patients with stage II and III colon cancer. Participants in the study will take either aspirin or a placebo every day for up to five years. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor the participants’ health to see if the cancer returns and to track their overall survival. The main goal is to see if taking aspirin can help improve survival rates over five years. The study will also look at how long patients remain free from cancer and how long they can continue the treatment without any issues. This research aims to provide valuable insights into the potential benefits of aspirin for patients who have undergone surgery for colon cancer.

The purpose of the study is to see how well the combination treatment works compared to the single medication in preventing the return of melanoma after it has been surgically removed. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. Some participants may receive a placebo, which is a substance with no active medication. The study will last for up to 12 months, during which time participants will receive regular infusions and be monitored for any changes in their condition.

Throughout the study, researchers will keep track of how long participants remain free from melanoma returning, as well as other important health outcomes. These include how long participants live without the cancer spreading to other parts of the body, overall survival rates, and any side effects experienced. The study will also assess changes in participants’ quality of life and physical functioning. This information will help determine the effectiveness and safety of the combination treatment compared to the single medication.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

The main aim of the trial is to assess whether the drug improves daytime alertness in participants with this condition. Volunteers will be randomly assigned to receive either the active medication or the inactive comparator, and they will take the assigned tablet each day for approximately twelve weeks. Throughout the study period, participants will attend regular visits where simple questionnaires and brief safety checks will be performed to monitor how they feel and to ensure the treatment is well tolerated.

The main goal of the trial is to see whether multiple daily doses of the medication are safe and well tolerated in healthy volunteers and to gather early information on its pharmacokinetics, which means how the body absorbs, distributes, and removes the drug. Researchers will watch for any adverse event (side effect) and will measure the amount of drug in the blood, referred to as plasma, at several time points to understand how long the drug stays in the system, its half‑life, and how quickly it is cleared.

Participants will take the assigned capsule once each day for seven days. During this period, short clinic visits will be scheduled to collect blood samples and check for any side effects. After the final dose, additional blood draws will be done to complete the safety checks and the drug‑level measurements, after which participants will be monitored for a short follow‑up period.

The purpose of the study is to determine the drug’s bioavailability, meaning how much of the medication reaches the bloodstream when taken as a pill compared with the tiny IV dose. By comparing the two administrations, researchers can learn how the body absorbs and processes the medication.

Volunteers will first swallow the tablet, then, after a short waiting period, receive the IV microdose. Blood samples will be collected at several time points over the next few hours to measure the amount of drug in the blood. The entire procedure is completed within a single visit, and no additional treatments are given.